Scenic Biotech

Our Head of Translational Research, Guido Hartmann will be leading a presentation entitled “Discovery of a novel NPC disease modifier and development towards its clinical application” at next week's NATIONAL NIEMANN-PICK DISEASE FOUNDATION Family Support & Medical Conference (NNPDF) on July 12 at 11:45 am MDT in Salt Lake City. The NNPDF conference is a unique opportunity to connect with expert clinicians, researchers, and families affected by Niemann-Pick disease.   Join us to learn about the latest advances in evolution-inspired medicine and how Scenic Biotech is pioneering modifier therapy to treat genetic disorders, including Niemann-Pick disease.   Together, as one voice, we can achieve urgently needed clinical treatments and support ongoing research towards a cure.   We look forward to seeing you there!   #NNPDF2024 #ModifierTherapy #NiemannPickDisease

Don’t miss the chance to meet Scenic’s Principal Scientist, Arthur de Jong, PhD at the Lysosomes and Endocytosis Gordon Research Conference held in Andover, New Hampshire on June 19th at 9:15 pm ET. Join Arthur’s oral presentation to learn how we have used our innovative modifier platform to identify and develop a product targeting Niemann Pick Type C that is now moving toward the clinic. 

#SavetheDate: Scenic’s Principal Scientist, Arthur de Jong, PhD will be discussing how we are using our unique modifier therapy approach to develop a novel treatment option for Niemann Pick Type C disease at the Lysosomes and Endocytosis Gordon Research Conference held in Andover, New Hampshire from June 16-21.

Connect with our CMO, Jens Wuerthner, MD PhD, at the Ara Parseghian Annual Scientific Conference, in Tucson, Arizona. Join Jens’ for his presentation to learn more about how Scenic has discovered a novel disease modifier for Niemann-Pick Type C and is currently advancing our innovative pipeline program toward clinical application.

Connect with our CMO, Jens Wuerthner, MD PhD, at the Ara Parseghian Annual Scientific Conference, in Tucson, Arizona. Join Jens’ for his presentation to learn more about how Scenic has discovered a novel disease modifier for Niemann-Pick Type C and is currently advancing our innovative pipeline program toward clinical application.

Don’t miss the chance to meet Frederik Gorter de Vries, Corporate Development Scenic Biotech, at the 24th Bio€quity Europe in San Sebastián, Spain, from May 12 to 14.   To schedule a one-to-one meeting with Frederik, visit: https://lnkd.in/dYrgwkAr

Today we announced a research collaboration with Bristol Myers Squibb to unlock the underlying genetic interactions of cellular pathways for several drug targets. This agreement is an important validation of Scenic’s Cell-Seq platform and its ability to not only identify modifier genes, but also to support our collaborators in crafting innovative medicines for patients with devastating conditions.   Access the full press release at: https://lnkd.in/dPZufpkb

Today we announced a research collaboration with Bristol Myers Squibb to unlock the underlying genetic interactions of cellular pathways for several drug targets. This agreement is an important validation of Scenic’s Cell-Seq platform and its ability to not only identify modifier genes, but also to support our collaborators in crafting innovative medicines for patients with devastating conditions.   Access the full press release at: https://lnkd.in/dPZufpkb

Scenic’s Head of Business Development, Sebastian Franzinger, will be presenting tomorrow at the @World Orphan Drug Congress USA 2024 in Boston. Join Sebastian for his presentation, entitled “NPC, Galactosemia and Barth Syndrome: Developing Modifier Therapies for Neurological and Metabolic Disorders,” at 4:10 pm ET to learn more about the development of our most advanced programs and how our modifier therapy approach can be applied to a variety of rare diseases.   To learn more about our therapeutic programs, visit: https://lnkd.in/dbUUKVgG   #WODC2024 #WODCUSA #raredisease

Schedule a virtual 1:1 meeting with Sebastian Franzinger, Scenic’s Head of Business Development at #AsiaBio. Sebastian welcomes the opportunity to introduce participants to our radically new approach to treating genetic disorders, including cancer and rare diseases, with our modifier therapies.   Access the conference’s partnering platform at https://lnkd.in/d_Dmxt6p.